| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MT3 |
| Uniprot No | P25713 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-68aa |
| 氨基酸序列 | MDPETCPCPSGGSCTCADSCKCEGCKCTSCKKSCCSCCPAECEKCAKDCV CKGGEAAEAEAEKCSCCQ |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MT3(金属硫蛋白3)重组蛋白的模拟参考文献示例(仅供参考，具体文献需根据实际研究检索)：
1. **文献名称**: "Expression and Purification of Recombinant Human Metallothionein-3 in Escherichia coli"
**作者**: Smith J., et al.
**摘要**: 本研究描述了一种通过大肠杆菌表达系统高效生产重组人MT3蛋白的方法，优化了诱导条件与纯化步骤，并通过质谱验证其正确金属结合能力，为神经研究提供可靠蛋白来源。
2. **文献名称**: "Neuroprotective Role of Recombinant MT3 in Alzheimer’s Disease Models"
**作者**: Lee S., Kim D.
**摘要**: 文章探讨了重组MT3蛋白在阿尔茨海默病细胞模型中的保护作用，证明其通过螯合过量锌离子减轻β-淀粉样蛋白毒性，提示其潜在治疗价值。
3. **文献名称**: "Structural Characterization of Recombinant MT3 Using NMR Spectroscopy"
**作者**: García R., et al.
**摘要**: 通过核磁共振技术解析了重组MT3的溶液结构，揭示了其与MT1/MT2亚型的结构差异，阐明了MT3特异性神经抑制活性的分子基础。
4. **文献名称**: "Functional Comparison of Recombinant MT3 Isoforms in Antioxidant Response"
**作者**: Chen L., Wang H.
**摘要**: 研究对比了不同重组MT3变异体在细胞抗氧化应激中的功能差异，发现特定半胱氨酸残基对其自由基清除能力的关键影响。
---
**注意**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词(如"recombinant MT3"、"Metallothionein 3 expression")。建议使用近期研究(2015年后)以获取最新方法与应用进展。
**Background of MT3 Recombinant Protein**
MT3. also known as Metallothionein-3. is a small, cysteine-rich protein belonging to the metallothionein (MT) family, which plays critical roles in metal ion homeostasis, detoxification, and protection against oxidative stress. Discovered in 1991. MT3 is distinct from other MT isoforms (MT1. MT2) due to its unique tissue-specific expression, primarily in the central nervous system (CNS), and its association with neurodegenerative disorders. Its structure includes two metal-binding domains (α and β clusters) that coordinate zinc, copper, or other metal ions, influencing cellular metal metabolism and redox balance.
Recombinant MT3 is produced using biotechnological methods, such as cloning the MT3 gene into bacterial (e.g., *E. coli*) or mammalian expression systems, followed by purification. This engineered protein retains the metal-binding and antioxidant properties of native MT3. making it a valuable tool for research. Studies highlight its neuroprotective functions, including mitigating oxidative damage, regulating synaptic zinc levels, and modulating inflammatory responses. Notably, MT3 is linked to Alzheimer’s disease, as its expression is reduced in affected brains, correlating with pathological metal accumulation and neuronal death.
Research applications of recombinant MT3 span *in vitro* and *in vivo* models to explore its therapeutic potential in neurodegenerative diseases, cancer, and metal toxicity. Its ability to chelate excess metals or deliver therapeutic ions underscores its versatility in biomedical studies. Despite progress, challenges remain in understanding its precise mechanisms and optimizing delivery methods for clinical use. Overall, MT3 recombinant protein serves as a pivotal molecule for unraveling metal-related pathophysiology and developing targeted therapies.
×
